替雷利珠单抗联合经肝动脉化疗栓塞治疗晚期肝癌的临床研究OA
Clinical Study of Telalipizumab Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Liver Cancer
目的 探讨替雷利珠单抗联合经肝动脉化疗栓塞(TACE)治疗晚期肝癌的效果.方法 72例晚期肝癌患者随机分为两组各36例.对照组采用TACE治疗,观察组在对照组基础上于术后3～5 d应用替雷利珠单抗治疗.比较两组的治疗效果、血清指标以及不良反应.结果 观察组的疾病控制率高于对照组(P＜0.05).治疗后,观察组的VEGF、AFP水平均低于对照组(P＜0.05).两组的药物不良反应发生率比较,差异均无统计学意义(P＞0.05).结论 TACE联合替雷…查看全部>>
Objective To explore the effect of telalipizumab combined with transcatheter arterial chemoembolization(TACE)in the treatment of advanced liver cancer.Methods 72 patients with advanced liver cancer were randomly divided into two groups,with 36 cases in each group.The control group was treated with TACE,and the observation group was treated with telalipizumab at 3～5 days after surgery on the basis of the control group.The therapeutic effect,serum indicators a…查看全部>>
袁生武;刘凯
郑州大学第五附属医院介入科,河南郑州 450052郑州大学第五附属医院介入科,河南郑州 450052
临床医学
替雷利珠单抗经肝动脉化疗栓塞晚期肝癌
TelalipizumabTranscatheter arterial chemoembolizationAdvanced liver cancer
《临床医学工程》 2023 (12)
1705-1706,2
评论